Hydroxyurea to lower TCD velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort
Robert O. Opoka, Heather A. Hume, Teresa S. Latham, Adam Lane, Olatundun Williams, Jennifer Tymon, Maria Nakafeero, Phillip Kasirye, Christopher M. Ndugwa, Chandy C. John, Russell E Ware
Haematologica October 2019 : haematol.2019.231407; doi:10.3324/haematol.2019.231407

Author Affiliations

  1. Robert O. Opoka1,
  2. Heather A. Hume2,
  3. Teresa S. Latham3,
  4. Adam Lane3,
  5. Olatundun Williams4,
  6. Jennifer Tymon5,
  7. Maria Nakafeero3,
  8. Phillip Kasirye1,
  9. Christopher M. Ndugwa1,
  10. Chandy C. John6 and
  11. Russell E Ware7,*
  1. 1 Department of Paediatrics and Child Health, Makerere University, Kampala Uganda;
  2. 2 Makerere University, Kampala Uganda and Université de Montréal, Canada;
  3. 3 Department of Pediatrics, Cincinnati Children Hospital Medical Center, Cincinnati, USA;
  4. 4 Ann and Robert H. Lurie Children Hospital of Chicago, Chicago, USA;
  5. 5 St. Luke University Health Network, Bethlehem, USA;
  6. 6 Ryan White Center for Infectious Diseases and Global Health, Indianapolis, USA;
  7. 7 Global Health Center, Cincinnati Children Hospital Medical Center, Cincinnati, USA
  1. ↵* Corresponding author; email: russell.ware{at}cchmc.org

Abstract

*_*

  • Received July 5, 2019.
  • Accepted October 24, 2019.
Back to top

Keywords

Hemoglobinopathies
Hydroxyurea
sickle cell anemia
Stroke
Transcranial Doppler
Email
Citation Tools

Jump To

What about you?
Tell us your interests and get all the new contents of Haematologica in advance